Clinical trials: Insulin Treated Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2
Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion
The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose, glycated hemoglobin (A1C), and fructosamine were…
- Trial name
- NCT02397447
- Testing
- Momordica charantia
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Diabetes Mellitus, Diabetes Mellitus, Type 2
Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT
To compare the effects of different initial insulin dose regimens during the short-term insulin intensive treatment on time to glycemic goal, hypoglycemia prevalence, glycemic variability and other safety problems in newly…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05084079
- Testing
- CSII with formula-based initial insulin regimen, CSII with weight-based initial insulin regimen
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sun Yat-sen University
Cardiovascular Risk Factor, Diabetes Mellitus, Type 2
Evaluation of a Physical Activity Referral Scheme
The study will evaluate the effectiveness of a co-developed exercise referral scheme. Participants will be recruited to one of three groups 1. Co-developed exercise referral scheme, 2. Usual care exercise referral scheme, 3.
- Conditions
- Cardiovascular Risk Factor, Diabetes Mellitus, Type 2, Anxiety, Depression
- Trial name
- NCT03490747
- Testing
- Physical activity referral scheme, Usual care exercise referral scheme
- Where
- United Kingdom
- Volunteers
- 68 people
- Sponsor
- Paula Watson
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
Designed to evaluate dose response of force-titrated prandial administration of TI as compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled
- Trial name
- NCT00511732
- Testing
- Technosphere Insulin
- Volunteers
- 227 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus, Postprandial Hyperglycemia
Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)
The postprandial phase in diabetic patients is characterized by a rapid increase in blood glucose levels, increase in platelet aggregation, LDL oxidation and over production of thrombin.
- Trial name
- NCT00771693
- Testing
- Insulin aspart (Novorapid®)
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 2, Insulin Resistance
Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study
Based in a surgery technique studied in a non-obese diabetic mouse model by Rubino and Marescaux(2004), wich reversed diabetes in those animals, we have performed a previous study in human volunteers with type 2 diabetes and…
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Obesity
- Trial name
- NCT00566215
- Testing
- Duodenal exclusion plus omentectomy, Duodenal exclusion without omentectomy
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes Treated With Insulin
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
- Trial name
- 2IQP (NCT05785832)
- Testing
- t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
- Where
- 21 sites in United States, Canada
- Volunteers
- 319 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 2 Diabetes
Evaluating an Analogy-Based Consultation Approach for Insulin-Treated Type 2 Diabetes Patients
The goal of this retrospective interventional study is to learn whether a new consultation approach called M2-PRIME can help improve blood sugar control in people with type 2 diabetes who use insulin and have high blood sugar…
- Trial name
- ANALOGIES01 (NCT07265245)
- Testing
- M2-PRIME
- Where
- Malaysia
- Volunteers
- 106 people
- Sponsor
- Ministry of Health, Malaysia
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
This study is conducted to test the hypothesis that in type 2 diabetic adults with fatty liver who are resistant to metformin, treatment with liraglutide in combination with metformin will cause an absolute reduction in liver fat…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
- Trial name
- LIRAINS (NCT01399645)
- Testing
- Liraglutide-metformin vs insulin-metformin
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Diabetes
Point-of-Care Glucose Testing and Insulin Supplementation
Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting.
- Trial name
- POC (NCT01702311)
- Testing
- Bedtime insulin Aspart (Novolog)
- Where
- 2 sites in United States
- Volunteers
- 235 people
- Sponsor
- Emory University
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT
The goal of this study is to perform a first-in-humans trial of a fully integrated, automated, closed-loop blood glucose control system designed for inpatient use.
- Trial name
- NCT04227626
- Testing
- GlucoSTAT
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.
- Trial name
- NCT00213070
- Testing
- Miglitol
- Where
- 16 sites in Japan
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Type 2 Diabetes Treated With Insulin
Assessment of an Integrated Continuous Glucose Monitor and Insulin Injection Port in Type 2 Diabetes
THE GOALS of the STUDY are: (1) Determine if this novel continuous glucose monitoring (CGM) - multiple daily injection (MDI) port functions for 7 days in persons with Type 2 diabetes (T2D); (2) Measure the duration of glucose…
- Trial name
- NCT05185518
- Testing
- Use of novel insulin injection port
- Volunteers
- 18 people
- Sponsor
- Pacific Diabetes Technologies
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
This study is designed to demonstrate that addition of rosiglitazone (4mg) to insulin in Type 2 diabetes mellitus subjects who have not achieved glycemic goals on insulin injections alone is efficacious in terms of improving…
- Trial name
- NCT00349427
- Testing
- Rosiglitazone 4 mg
- Where
- 10 sites in China
- Volunteers
- 256 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- REIMAGINE 3 (NCT06323161)
- Testing
- Cagrilintide, Semaglutide
- Where
- 61 sites in United States, China and 4 more
- Volunteers
- 274 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
Primary objective: Efficacy assessment of the percentage of positive responders patients receiving Lantus plus glucophage association.
- Trial name
- GALATEE (NCT00653302)
- Testing
- Lantus (insulin glargine) + Glucophage (Metformin)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Sanofi
Ischemic Heart Disease, Myocardial Infarction
Polyamine Treatment in Elderly Patients With Coronary Artery Disease
The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.
- Conditions
- Ischemic Heart Disease, Myocardial Infarction, Cardiovascular Diseases, Hypertensive Heart Disease
- Trial name
- PolyCAD (NCT06186102)
- Testing
- Spermidine
- Where
- Denmark
- Volunteers
- 187 people
- Sponsor
- University of Aarhus
Type 2 Diabetes
CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
This is a trial to determine if patients who are well controlled and on basal insulin are treated with excessive basal dose.
- Trial name
- NCT01548222
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Diabetes Care Center